Response by Chao et al to Letter Regarding Article, “Oral Anticoagulation in Very Elderly Patients With Atrial Fibrillation: A Nationwide Cohort Study”

We thank Aldaas et al for their comments regarding our recently published article on stroke prevention in very elderly patients (90 years of age) with atrial fibrillation (AF). In Taiwan, dabigatran was introduced in June 2012, rivaroxaban in February 2013, and apixaban in June 2014, and therefore patient numbers treated with apixaban were limited during our study period (years 2012-2015).